With nearly seven million Americans currently suffering from Alzheimer's disease, the effort to understand what causes it and how it could be treated effectively is urgent. Over the last several decades, research on this dementia has focused largely on amyloid plaque (also called amyloid-beta) in the brain as the sole cause. Consequently, drug companies have developed medications that can pull plaque out of the brain. Medicines like aducanumab (Aduhelm), lecanemab (Leqembi) and donanemab (Kisunla) do that pretty well. Unfortunately, though, the patients don't get better. At best, they decline a little more slowly. Could putting all the focus on amyloid-beta have been a mistake?
This week, we explore the evidence that some respected researchers in the field of Alzheimer's disease took shortcuts or even manipulated their data to get the results they wanted. How did our guests detect fraud and arrogance in this research?
